Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propantheline is a small molecule antimuscarinic (anticholinergic) agent used primarily to treat or prevent spasms in the muscles of the gastrointestinal tract (such as in irritable bowel syndrome), peptic ulcer disease, urinary incontinence, hyperhidrosis (excessive sweating), and other conditions involving smooth muscle spasm. It works by blocking muscarinic acetylcholine receptors on smooth muscle cells and secretory glands, thereby inhibiting involuntary contractions and reducing secretions such as gastric acid and sweat. At higher doses it may also exhibit nicotinic effects resulting in neuromuscular blockade. The drug is typically administered orally as propantheline bromide. Propantheline has been largely replaced by newer agents for many indications but remains available for certain uses. It is sometimes prescribed off-label for excessive salivation during dental procedures. Its side effect profile includes typical anticholinergic effects such as dry mouth, blurred vision, constipation, tachycardia, urinary retention and decreased sweating.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propantheline.